Nootropics
Rasagiline
A prescription MAO-B inhibitor for Parkinson’s disease; symptom treatment does not establish disease modification or healthy cognitive enhancement.
Established Parkinson’s indication; inconsistent disease-modification trial
Practical use
Reviewed practical notes
- Separate symptom relief and progression
- A Parkinson’s indication does not prove disease modification.
- Include nonprescription products
- Cough medicines and supplements can be relevant to the interaction review.
- Report behavioral changes
- New hallucinations, excessive sleepiness or unusual urges warrant prompt discussion with the treating clinician.
Overview
Rasagiline inhibits monoamine oxidase B and is a medicine for Parkinson’s disease under the cited US prescribing information. A medicine that improves symptoms can still have uncertain effects on the underlying progression of disease. Its placement in a nootropics catalog does not change its medical indication.
Risks and limitations
The label warns about serious interactions, including serotonin syndrome with certain serotonergic medicines, blood-pressure effects and excessive sleepiness. Hallucinations and impulse-control problems are also concerns. Prescription, nonprescription and supplement exposures all matter during medication review.
How to read this
The ADAGIO trial tested whether earlier treatment had a lasting advantage over delayed treatment. Its inconsistent results across the two experimental conditions mean it should not be presented as settled proof of neuroprotection or slower Parkinson’s progression.
Research explained
ADAGIO delayed-start trial
Who was studied
1,176 participants with early, untreated Parkinson’s disease followed in a 72-week randomized trial.
What was found
One active-treatment condition met all three prespecified criteria used to assess a possible disease-modifying effect; the other did not.
What it cannot establish
The discordant findings require caution. A lasting symptom difference and modification of disease biology are difficult to separate, and this was not a healthy-volunteer cognition trial.
Read the original studyInteraction review is part of the indication
The US label includes contraindicated combinations with several opioids, other monoamine oxidase inhibitors, dextromethorphan and certain other agents. This is not a complete interaction list; a current product-label review is needed before medication changes.
Supporting sourceCorrection history is preserved
A later correction addresses a table denominator in ADAGIO. This guide does not reproduce the affected adverse-event table or infer new safety rates from it.
Supporting sourceSources
Current US rasagiline prescribing information
Sources checked 2026-10-01.
General education; not a personal treatment plan.